Project Grant HT94252311001
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$718K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
The University of Oklahoma Health Sciences Center was awarded an $864,781 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from April 1, 2023 to March 31, 2026 targeting DCLK1-driven chemoresistance in ovarian cancer. The goal aligns with the Military Medical Research and Development program's focus on innovative medical solutions for Service Members and the public through...
The federal Project Grant award of $541,837 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports the University of Oklahoma Health Sciences Center Division in conducting research on "DRUG-TARGETING ORP4 AS A PRECISION OVARIAN CANCER TARGET". This 4-year project, commencing on May 1, 2025 and ending on April 30, 2029, aims to develop innovative cancer prevention and treatment strategies through advanced biomedical research....
The University of Oklahoma Health Sciences Center Division was awarded a $1,144,000 Project Grant (Federal Grant Award ID: HT94252510311) on May 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public, with a particular emphasis on conditions relevant to military personnel and...
The University of Oklahoma (OU) was awarded a $1,051,250 Project Grant from the Defense Health Agency to conduct research on the re-expression of miR-195 as a therapeutic strategy for chemoresistant ovarian cancer. This research falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform health care for service members and the American public. The project is scheduled to run from August 15, 2023, to August 14, 2027. As a public...
The Defense Health Agency awarded a $602,814 Project Grant to the University of Nebraska Medical Center (UNMC) under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from November 1, 2024 to October 31, 2027, supports research to investigate "Targeting Extracellular Nucleoside Metabolism as a Strategy to Potentiate the Effects of Immunotherapy in Pancreatic Ductal Adenocarcinoma." The project aims to explore innovative approaches...
The federal Project Grant award, with ID HT94252510262, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $427,109.00 award, with a performance period from May 15, 2025 to May 14, 2027, supports research by the University of Oklahoma Health Sciences Center to target DCLK1-mediated glutamine addiction in chemoresistant ovarian cancer metastases. This federally funded project aims to develop innovative...
The University of Oklahoma Health Sciences Center Division has been awarded a $144,992 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from November 1, 2024 to October 31, 2026, will support advanced biomedical research focused on "Vascular Regulation of Immunosuppression in Glioblastoma." The funding will enable the university to conduct...
This $602,550 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) supports adoptive cellular therapy research for pancreatic cancer. The awardee, the University of Nebraska Medical Center (UNMC), will conduct innovative biomedical research to develop novel therapeutic approaches, perform clinical trials, and provide technical expertise in this critical medical field. As a prominent academic research...
Oregon Health & Science University was awarded a $494,340 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2022 through July 2025 to elucidate mechanisms of rapid metastatic recurrence in pancreatic ductal adenocarcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
Oregon Health & Science University was awarded a $506,554 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2022 through July 2025 to elucidate mechanisms of rapid metastatic recurrence in pancreatic ductal adenocarcinoma. Through basic, applied, and advanced biomedical research supported by this program, the Army aims to transform military and public health care by...